Fledgling biotech Syntimmune looks to take flight in the clinic with a new CEO and a slightly less virtual business model
Syntimmune is still a largely untethered, virtual biotech with a tiny crew of staffers backed by a platoon of consultants. But today it’s just a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
